Results 231 to 240 of about 110,079 (354)

Effects of cell therapy on seizures in animal models of epilepsy: Systematic review and meta‐analysis

open access: yesEpilepsia, EarlyView.
Abstract This study was undertaken to systematically evaluate the efficacy of cell therapy in reducing seizures in animal models of chronic epilepsy. Three databases, Ovid MEDLINE, Ovid Embase, and Web of Science, were searched using predetermined eligibility criteria.
Afaf S. Altalhi   +6 more
wiley   +1 more source

Pharmacokinetics and tolerability of single‐dose Staccato® alprazolam in adolescents with epilepsy, and population pharmacokinetic analysis to support dose selection in adolescents

open access: yesEpilepsia, EarlyView.
This is a graphical representation of the abstract and article highlights. Abstract Objective Staccato® alprazolam is a hand‐held inhalation device that provides rapid systemic delivery of alprazolam through the intrapulmonary route. This trial explored the pharmacokinetics and tolerability of single‐dose Staccato alprazolam 2 mg in adolescents with ...
Pavel Klein   +12 more
wiley   +1 more source

Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A‐derived epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective Neuropeptides have garnered great interest as potential treatments for epilepsy due to their impact on neuronal excitability through modulation of ion channels and neurotransmitter receptor activity. Neuropeptide Y (NPY) is a 36‐amino acid neuropeptide that is expressed primarily by γ‐aminobutyric acidergic (GABAergic) interneurons ...
Samantha L. Reed   +8 more
wiley   +1 more source

Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy

open access: yesEpilepsia, EarlyView.
Abstract Objectives Drug‐resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one‐third of patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promise in clinical trials. However, real‐world data on its use, especially economic evaluations, remain limited.
Valentina Perrone   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy